EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

High Circulating Dipeptidyl Peptidase 3 Predicts Mortality and Need for Organ Support in Cardiogenic Shock: An Ancillary Analysis of the ACCOST-HH Trial

Adrien Picod, Hugo Nordin, Dominik Jarczak, Tanja Zeller, Claire Oddos, Karine Santos, Oliver Hartmann, Antoine Herpain, Alexandre Mebazaa, Stefan Kluge, Feriel Azibani, Mahir Karakas

Journal of Cardiac Failure · 2025-01 · 31 (1) · 29-36

DOI: 10.1016/j.cardfail.2024.03.014 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiac Failure, 2025-01. Verfasst von Adrien Picod und 11 weiteren Autor:innen. Beteiligte Einrichtung: INSERM UMR-S 942 MASCOT - Paris - Cité University, Paris, France. Hauptthemen laut MEDLINE: Shock, Cardiogenic, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institut National de la Santé et de la Recherche Médicale, Else Kroner-Fresenius Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cardiogenic shock (CS) is burdened with high mortality. Efforts to improve outcome are hampered by the difficulty of individual risk stratification and the lack of targetable pathways. Previous studies demonstrated that elevated circulating dipeptidyl peptidase 3 (cDPP3) is an early predictor of short-term outcome in CS, mostly of ischemic origin. Our objective was to investigate the association between cDPP3 and short-term outcomes in a diverse population of patients with CS. METHODS AND RESULTS: cDPP3 was measured at baseline and after 72 hours in the AdreCizumab against plaCebO in SubjecTs witH cardiogenic sHock (ACCOST-HH) trial. The association of cDPP3 with 30-day mortality and need for organ support was assessed. Median cDPP3 concentration at baseline was 43.2 ng/mL (95% confidence interval [CI], 21.2-74.0 ng/mL) and 77 of the 150 patients (52%) had high cDPP3 over the predefined cutoff of 40 ng/mL. Elevated cDPP3 was associated with higher 30-day mortality (adjusted hazard ratio [aHR] = 1.7; 95% CI, 1.0-2.9), fewer days alive without cardiovascular support (aHR, 3 days [95% CI, 0-24 days] vs aHR, 21 days [95% CI, 5-26 days]; P < .0001) and a greater need for renal replacement therapy (56% vs 22%; P < .0001) and mechanical ventilation (90 vs 74%; P = .04). Patients with a sustained high cDPP3 had a poor prognosis (reference group). In contrast, patients with an initially high but decreasing cDPP3 at 72 hours had markedly lower 30-day mortality (aHR, 0.17; 95% CI, 0.084-0.34), comparable with patients with a sustained low cDPP3 (aHR, 0.23; 95% CI, 0.12-0.41). The need for organ support was markedly decreased in subpopulations with sustained low or decreasing cDPP3. CONCLUSIONS: The present study confirms the prognostic value of cDPP3 in a contemporary population of patients with CS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Shock, CardiogenicDipeptidyl-Peptidases and Tripeptidyl-PeptidasesHumansMaleFemaleAgedMiddle AgedBiomarkersPredictive Value of TestsPrognosisDouble-Blind Method

Stichwörter der Autor:innen

Cardiogenic shockcirculatory failuredipeptidyl peptidase 3

Substanzen

BiomarkersDipeptidyl-Peptidases and Tripeptidyl-Peptidases

Autor:innen und Institutionen

  • INSERM UMR-S 942 MASCOT - Paris - Cité University, Paris, France.
  • Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • University Center of Cardiovascular Science, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Cardiology, University Heart & Vascular Center Hamburg, Ham…
  • 4TEEN4 Pharmaceuticals Gmbh, Hennigsdorf, Germany.
  • SphingoTec Gmbh, Hennigsdorf, Germany.
  • Experimental Laboratory of Intensive Care, Université Libre de Bruxelles, Brussels, Belgium; St. Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Förderung

  • Institut National de la Santé et de la Recherche Médicale
  • Else Kroner-Fresenius Foundation

Zitieren

APA

Picod, A., Nordin, H., Jarczak, D., Zeller, T., Oddos, C., Santos, K., Hartmann, O., Herpain, A., Mebazaa, A., Kluge, S., Azibani, F., & Karakas, M. (2025). High Circulating Dipeptidyl Peptidase 3 Predicts Mortality and Need for Organ Support in Cardiogenic Shock: An Ancillary Analysis of the ACCOST-HH Trial. Journal of Cardiac Failure, 31(1), 29-36. https://doi.org/10.1016/j.cardfail.2024.03.014

Vancouver

Picod A, Nordin H, Jarczak D, Zeller T, Oddos C, Santos K, et al. High Circulating Dipeptidyl Peptidase 3 Predicts Mortality and Need for Organ Support in Cardiogenic Shock: An Ancillary Analysis of the ACCOST-HH Trial. Journal of Cardiac Failure. 2025;31(1):29-36. doi:10.1016/j.cardfail.2024.03.014

BibTeX
@article{Picod2025,
  author = {Picod, Adrien and Nordin, Hugo and Jarczak, Dominik and Zeller, Tanja and Oddos, Claire and Santos, Karine and Hartmann, Oliver and Herpain, Antoine and Mebazaa, Alexandre and Kluge, Stefan and Azibani, Feriel and Karakas, Mahir},
  title = {High Circulating Dipeptidyl Peptidase 3 Predicts Mortality and Need for Organ Support in Cardiogenic Shock: An Ancillary Analysis of the ACCOST-HH Trial},
  journal = {Journal of Cardiac Failure},
  year = {2025},
  volume = {31},
  number = {1},
  pages = {29--36},
  doi = {10.1016/j.cardfail.2024.03.014}
}
Kostenlos starten →